Nephrocare Health Services: Pursuant to Reg 30 of SEBI Listing Regulations, we hereby inform you that Nephrocare Health Services,…
Nephrocare Health Services (NEPHROPLUS) filed a disclosure titled "Pursuant to Reg 30 of SEBI Listing Regulations, we hereby inform you that Nephrocare Health Services, Philippines Inc., a step-down wholly owned subsidiary of the company has…". The company…
What happened
Nephrocare Health Services (NEPHROPLUS) filed a disclosure with the exchanges on 27 October 2026 at 07:42 PM titled "Pursuant to Reg 30 of SEBI Listing Regulations, we hereby inform you that Nephrocare Health Services, Philippines Inc., a step-down wholly owned subsidiary of the company has…".
Company snapshot
Nephrocare Health Services is a small-cap company in the Healthcare sector, with a market value of about ₹5,985 crore.
The stock last traded at ₹596.5, against a 52-week range of ₹446–₹781.5 (23.7% below the high).
Before this filing the shares had moved −20.4% over the month and −11.4% over three months. Average daily turnover over the last 20 sessions was about ₹48.17 crore.
Promoters held 63.85% at the end of Q1 FY27. Foreign institutions owned 8.78% and domestic institutions 9.05%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q3 FY26 | 260 | 32.2 | 3.43 |
| Q4 FY26 | 266 | 30.4 | 3.03 |
| Q1 FY27 | 282 | 32 | 3.19 |
What history shows
BCEIE's records show 7 previous m&a filings from the company since May 2026.
After those filings, the stock gained 1.6% on average the next trading day and was up 2.3% on average after five days (7 filings with price data).
Across 138 similar disclosures by other Healthcare companies, shares moved +0.5% on average the next day and +0.7% over five days; 56% of them rose the next day.
Market-wide, 2,167 m&a filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 18 Sept 2026 | Other Restructuring - Rationalisation and Consolidation of Company's… | +0.8% | −9.9% |
| 1 Sept 2026 | M&A | +2.5% | +6.4% |
| 17 Aug 2026 | M&A | +0.3% | −1.4% |
| 13 Aug 2026 | M&A | +2.6% | −0.7% |
| 10 Jun 2026 | M&A | +5.9% | +3.9% |
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
- 3 November 2026: Board meeting — Financial Results.
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.